scientific advisory board
Gary Onik, M.D.
Gary M. Onik, MD, while still in radiology residency training in 1982, at the University of California – San Francisco, described a brand new cancer treatment concept – a radiological procedure based on the possibility of image guided thermal tumor ablation (destruction). His new procedure demonstrated a brand new approach and novel techniques for destroying a tumor through freezing or heating and then leaving it in place to be removed by the body rather than by surgery.
This was the very first demonstration of its kind and with it Dr. Onik literally created an entirely new field of medicine around the concept of minimally invasive cancer tumor destruction and removal by normal bodily processes, rather than through surgical removal.
In 1982, using cryosurgical ablation under ultrasound guidance, he developed the first new potentially curative treatment for unresectable liver cancer patients. This work spawned the development of image-guided radio-frequency (RF) ablation of liver tumors, and subsequently the field of what is now a 4th branch of cancer treatment, called “Interventional Oncology”.
At the same time as his work on hepatic cancer ablation, Dr Onik. developed the instrumentation and techniques that allowed for the cryosurgical ablation of prostate cancer, which is now an accepted alternative to radiation and radical prostatectomy and the preferred treatment for patients with radiation-recurrent prostate cancer . His concept of “focal therapy” for prostate cancer, treating only the prostate tumor rather than the whole gland, similar to a breast lumpectomy, is now a major research and treatment initiative in all of the major prostate cancer centers in the world.
The 3D Prostate Mapping Biopsy, which he has pioneered, maps the exact location of the cancer in the prostate gland allowing safer and more efficacious treatment. (See video).
His most recent development of “Irreversible Electroporation” (IRE), embodied in the “NanoKnife”, is the first of its kind “non-thermal” tumor ablation modality, which is now being used to successfully treat inoperable pancreatic carcinoma. One recently published study indicated it can double overall survival time. This modality also promises effective treatment for other inoperable tumors including those of the head and neck and the brain.
After years of development and refinement leading to approval of the device, Dr. Onik is the physician with the most experience in the world using the NanoKnife, and is able to bring that experience along with the great breadth of his practice in tumor ablation to the treatment of recurrent prostate cancer.
The concepts and techniques he developed have had a major impact on the treatment of cancer patients throughout the world and his work has been recognized by awards given to him by major societies in both medicine and engineering.
In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies.
His latest work, using immunotherapy to treat metastatic cancer, offers hope those patients with literally no other options.
Neal D. Shore, M.D.
Neal D. Shore, M.D. is currently the Director and CPI at Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore is a Certified Physician Investigator (CPI) who has numerous publications in peer-reviewed journals and has lectured extensively on the treatment of prostate cancer and prostate enlargement. He has conducted more than 300 clinical trials, focused primarily on genitourinary (GU) oncology.
Dr. Shore serves on several industry boards as well as academic and advocacy networks, including the Society of Urologic Oncology, the Bladder Cancer Advocacy Network and World Journal of Urology. A graduate of Duke University, and Duke University Medical School, Dr. Shore completed a six-month clinical research fellowship in Pretoria, South Africa, and then completed his general surgery/urology training at New York Hospital Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City.
E. David Crawford, M.D.
E. David Crawford, M.D. is currently the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus.
Dr. Crawford is an internationally renowned urologist and an expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies.
Dr. Crawford has authored more than 600 scientific articles, as well as textbook and book chapters and is an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, and the Journal of Clinical Oncology. He is the Founder and Chairman of the Prostate Conditions Education Council, which is responsible for raising awareness and screening of millions of men for prostate health issues.
Stephen J. O'Day, M.D.
Steven J. O’Day, M.D. is the Executive Director of John Wayne Cancer Institute and Cancer Clinic at Providence Saint John’s Health Center, Director of Providence Los Angeles Regional Research, and a Professor of Medical Oncology. A board-certified medical oncologist, he is recognized as one of the world’s preeminent melanoma specialists and a leader of immune-based therapies across many cancer types.
Dr. O’Day has been at the forefront of new drug development and immunotherapies for cancers over the last two decades and has been a principal investigator for more than 100 clinical trials. He played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti- PD1 antibodies pembrolizumab and nivolumab.
Dr. O’Day completed his medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston.
Timothy P. Murphy, M.D.
Timothy P. Murphy, M.D. has spent the past 25 years as a clinician and clinical researcher in the field of interventional radiology. He was most recently an interventional radiologist at Rhode Island Hospital and a Full Professor, Research Track, in the department of Diagnostic Imaging at Alpert School of Medicine at Brown University.
He was the 2011 President of Society of Interventional Radiology and served on the Executive Council for nine years.
Dr. Murphy founded the Vascular Disease Research Center at Rhode Island Hospital, which conducts a range of clinical, pre-clinical, and epidemiologic studies of cardiovascular disease. He has conducted numerous clinical trials, including principal investigator of NIH funded Claudication: Exercise Vs. Endoluminal Revascularization Study (CLEVER) study and co-principal investigator of the NIH funded CORAL (Cardiovascular Outcomes with Renal Atherosclerotic Lesions).
Donald L. Trump, M.D.
Donald L. Trump, M.D. is a medical oncologist who specializes in the treatment of patients with genitourinary cancers, especially prostate and bladder cancer. Recently retired, he was the CEO and Executive Director of the Inova Schar Cancer Institute.
Dr. Trump was previously President and CEO of Roswell Park Cancer Institute in Buffalo, NY where he led a clinical research program in vitamin D-based cancer prevention and treatment, and care for patients with prostate cancer and other urologic cancers.
Over the span of his career, Dr. Trump has held clinical positions at The Johns Hopkins University, University of Wisconsin, Duke University, University of Pittsburgh, and State University of New York at Buffalo. He received his medical education and completed his residency and fellowship at Johns Hopkins University in Baltimore, MD.